Radiotheranostics combines disease-specific molecular imaging and radionuclide therapy. We present new and promising targets, tracers and isotopes for radiotheranostics and outline the road to clinical translation of the 177Lu–LNC1004 radiopharmaceutical, which has recently been approved by the US Food and Drug Administration (FDA) for a phase I clinical trial.
This is a preview of subscription content, log in via an institution to check access.
References
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M. & Lewis, J. S. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat. Rev. Clin. Oncol. 19, 534–550 (2022).
Herrmann, K. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 21, e146–e156 (2020).
Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).
Fanti, S. et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 19, E696–E708 (2018).
Dolgin, E. Radioactive drugs emerge from the shadows to storm the market. Nat. Biotechnol. 36, 1125–1127 (2018).
Bauer, D., Sarrett, S. M., Lewis, J. S. & Zeglis, B. M. Click chemistry: a transformative technology in nuclear medicine. Nat. Protoc. 18, 1659–1668 (2023).
Sartor, O. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
Zhang, J. et al. From bench to bedside-the Bad Berka experience with first-in-human studies. Semin. Nucl. Med. 49, 422–437 (2019).
Strosberg, J. R. et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 1752–1763 (2021).
Wen, X. et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 12, 422–433 (2022).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
X.C. is the co-founder and CTO of Yantai LNC Biotechnology. J.Z. is the CMO of Yantai LNC Biotechnology. The other authors declare no competing interests.
Additional information
Related links
US $5.32 billion in 2022 with a compound annual growth rate of about 10.7% to reach US $12.18 billion by 2030: https://www.databridgemarketresearch.com/reports/global-radiopharmaceuticals-market
Rights and permissions
About this article
Cite this article
Zhang, J., Zhao, T., Jakobsson, V. et al. Clinical translation of radiotheranostics for precision oncology. Nat Rev Bioeng 1, 612–614 (2023). https://doi.org/10.1038/s44222-023-00106-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44222-023-00106-9
- Springer Nature Limited